Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality. We do this through our proven brand and sales know-how, strong expertise across a number of key therapeutic categories, and deep experience in all critical Asia Pacific countries. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.
With more than 4,000 employees throughout Asia Pacific, Invida operates throughout the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands as well as licensed products from biotech and multinational companies. Partnering is a critical component of Invida’s business model.
Invida operates in the fastest growing healthcare markets worldwide, increasing at an annual compounded growth rate of 12 percent, more than double the global growth rate for the sector. Today, the Asia Pacific markets represent approximately US$50 billion and 10 percent of worldwide pharmaceutical sales.* With China and India among top growth contributors globally, Invida is currently implementing a long-term strategy to establish itself as a leader in these rapidly expanding markets through targeted investments.
As multinational pharmaceutical companies re-prioritize portfolios and others seek experienced, trusted partners to enter large and emerging markets, Invida provides the option of a single reliable partner in the Asia Pacific markets.
History
Invida was formed in 2005 by a powerful strategic partnership of Quintiles, the world’s leading pharmaceutical services organization; Temasek Holdings, one of the world’s largest investment companies, and Zuellig Group, the largest pharmaceutical distribution and supply chain management network in Asia Pacific.
Invida was formed in 2005 by a powerful strategic partnership of Quintiles, the world’s leading pharmaceutical services organization; Temasek Holdings, one of the world’s largest investment companies, and Zuellig Group, the largest pharmaceutical distribution and supply chain management network in Asia Pacific.
Invida carries with it the history, relationships, and strong track record of its strategic partners. The subsidiaries of Invida, Pharmalink, Inovail and Innovex, are today being integrated into a single global brand, Invida, to serve the rapidly growing needs of its global partners and stakeholders.
*source: McKinsey & Company
